As of 2025-09-17, the EV/EBITDA ratio of Kymera Therapeutics Inc (KYMR) is -10.39. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KYMR's latest enterprise value is 3,156.07 mil USD. KYMR's TTM EBITDA according to its financial statements is -303.76 mil USD. Dividing these 2 quantities gives us the above KYMR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.7x - 11.7x | 9.2x |
| Forward P/E multiples | 10.4x - 16.3x | 12.1x |
| Fair Price | (39.37) - (45.15) | (40.61) |
| Upside | -180.7% - -192.6% | -183.2% |
| Date | EV/EBITDA |
| 2025-09-16 | -10.39 |
| 2025-09-15 | -10.04 |
| 2025-09-12 | -9.97 |
| 2025-09-11 | -9.78 |
| 2025-09-10 | -9.14 |
| 2025-09-09 | -9.14 |
| 2025-09-08 | -9.09 |
| 2025-09-05 | -9.15 |
| 2025-09-04 | -8.84 |
| 2025-09-03 | -9.10 |
| 2025-09-02 | -8.49 |
| 2025-08-29 | -8.61 |
| 2025-08-28 | -8.74 |
| 2025-08-27 | -8.86 |
| 2025-08-26 | -9.23 |
| 2025-08-25 | -8.75 |
| 2025-08-22 | -9.29 |
| 2025-08-21 | -8.93 |
| 2025-08-20 | -8.88 |
| 2025-08-19 | -8.93 |
| 2025-08-18 | -9.18 |
| 2025-08-15 | -8.94 |
| 2025-08-14 | -8.69 |
| 2025-08-13 | -8.50 |
| 2025-08-12 | -8.29 |
| 2025-08-11 | -7.78 |
| 2025-08-08 | -8.47 |
| 2025-08-07 | -8.52 |
| 2025-08-06 | -8.64 |
| 2025-08-05 | -9.02 |
| 2025-08-04 | -9.18 |
| 2025-08-01 | -9.02 |
| 2025-07-31 | -9.21 |
| 2025-07-30 | -9.28 |
| 2025-07-29 | -9.19 |
| 2025-07-28 | -9.31 |
| 2025-07-25 | -9.69 |
| 2025-07-24 | -9.70 |
| 2025-07-23 | -9.84 |
| 2025-07-22 | -9.68 |
| 2025-07-21 | -9.53 |
| 2025-07-18 | -9.78 |
| 2025-07-17 | -9.82 |
| 2025-07-16 | -9.62 |
| 2025-07-15 | -9.48 |
| 2025-07-14 | -9.48 |
| 2025-07-11 | -9.38 |
| 2025-07-10 | -9.55 |
| 2025-07-09 | -9.54 |
| 2025-07-08 | -9.13 |